N-butyldeoxynojirimycin (miglustat) ameliorates pulmonary fibrosis through inhibition of nuclear translocation of Smad2/3-Reference-Cited by-同舟云学术

N-butyldeoxynojirimycin (miglustat) ameliorates pulmonary fibrosis through inhibition of nuclear translocation of Smad2/3

Published:2023-04 Issue: Volume:160 Page:114405
ISSN:0753-3322
Container-title:Biomedicine & Pharmacotherapy
language:en
Short-container-title:Biomedicine & Pharmacotherapy

Author:

Nakamura Hiroyuki^ORCID,Zhou Yuan,Sakamoto Yuka,Yamazaki Ayako^ORCID,Kurumiya Eon,Yamazaki Risa^ORCID,Hayashi Kyota,Kasuya Yoshitoshi,Watanabe Kazuaki,Kasahara Junya,Takabatake Mamoru,Tatsumi Koichiro,Yoshino Ichiro,Honda Takuya^ORCID,Murayama Toshihiko

Funder

Japan Society for the Promotion of Science

Chiba University

Japan Agency for Medical Research and Development

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference51 articles.

1. Idiopathic pulmonary fibrosis-new insights;Verma;N. Engl. J. Med,2007

2. Novel therapeutic approaches for pulmonary fibrosis;Datta;Br. J. Pharm.,2011

3. Fibroblasts in fibrosis: novel roles and mediators;Keddall;Front Pharm.,2014

4. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling;Hinz;Am. J. Pathol.,2012

5. Role of sphingosine 1-phosphate signalling in tissue fibrosis;Donati;Cell Signal,2021

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fuzheng Huayu recipe inhibits bleomycin-induced pulmonary fibrosis in rats by inhibiting M2 polarization of macrophages via the oxidative phosphorylation pathway;Journal of Asian Natural Products Research;2024-07-03

2. Eliglustat exerts anti-fibrotic effects by activating SREBP2 in TGF-β1-treated myofibroblasts derived from patients with idiopathic pulmonary fibrosis;European Journal of Pharmacology;2024-03